Monday 20 July | Poster Exhibition

**Venue:** Hall B on the West Exhibition Level

**Presentation:** Monday 20 July, 12:30-14:30

The Poster Exhibition is open from Monday 20 - Wednesday 22 July from 10:00 to 18:30.

Posters will be displayed for the duration of the conference (Monday to Wednesday). Authors will stand by their posters between 12:30 and 14:30 to answer questions and provide further information on their study results on their presentation day. Late breaker posters are also displayed for the duration of the conference in the Poster Exhibition area.

**Track A > Basic Science**

**PEA001**
**Antibody diversity and function**

**MOPEA001**
Monoclonal antibodies using 1Vg-V regions from cows vaccinated with HIV gp140 require cysteine and tryptophan for high affinity Env trimer-specific binding

B. Heydarchi, R. Center, J. Guthbertson, J. Bebbington, G. Khoury, C. Mackenzie, B. Muller, C. Gonelli, D. Purcell

Australia

**PEA002-A003**
**B cells and alterations in subsets**

**MOPEA002**
Early initiation of treatment in primary HIV infection leads to temporary preservation of the B-cell compartment

G. de Bree, A. Wheatley, R. Lynch, M. Grijssen, J. Prins, J. Lange, S. Schmidt, A. Medermott, J. Mascola, R. Koup, Primo-SHM Cohort

Netherlands

**MOPEA003**
Numerical and phenotypic B-cell abnormalities and vaccine responses in HIV-exposed uninfected (HEU) children

C. Gravel, A. Le Campion, L. Raymonde-Marchand, M. Boucher, N. Lapointe, V. Lamarre, F. Kakkar, H.C.F. Côté, H. Soudeyns, CTHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

Canada

**PEA004**
**T-cell immune responses (CD4 and CD8)**

**MOPEA004**
Control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopes


Japan

**PEA005-A007**
**Mucosal immunity**

**MOPEA005**
Bacterial vaginosis is associated with loss of gamma delta T cells in the female reproductive tract


United States

**MOPEA006**
Effects of quadruple first-line ART on mucosal immunity and HIV persistence


United States

**MOPEA007**
Hormonal contraception and cervical immunity before and after HIV acquisition


United States

**PEA008-A011**
**Virus escape from adaptive immunity**

**MOPEA008**
Reporter assay to measure HIV-1 Nef-mediated evasion from T cells

G. Armole, X.T. Kuang, A. Shahid, E. Martin, Z.L. Brunme, M.A. Brockman

Canada

**MOPEA009**
Nef and Vpu accessory proteins from primary HIV-1 isolates protect infected cells from ADCC


Canada

**MOPEA010**
Novel approach to identify new ADCC-mediating antibodies targeting the HIV-1 envelope


Canada

**PEA012**
**HIV-1 controllers (including post-treatment controllers)**

**MOPEA013**
Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4 T cells in nonprogressors


United States

**PEA014-A015**
**Asymptomatic long term non-progression**

**MOPEA014**
Characterization of anti-gp41 antibodies eliciting viral neutralization and protecting against CD4 depletion in long-term non-progressors

V. Viellard, A. Samri, O. Lucar, J. Crouzet, D. Costagiola, P. Debré, French ALT Study Group

France

**MOPEA015**
CD40L-induced tunneling nanotube networks facilitate proinflammatory dendritic cell-mediated HIV-1 trans-infection of CD4+ T cells

C. Zaccard, R. Maillard, G. Rappocciolo, S. Watkins, C. Rinaldo

United States

**PEA016-A017**
**Highly exposed seronegative individuals (HESN)**

**MOPEA016**
Plasma and PBMC miRNA profile in sexually HIV-exposed seronegative individuals

I. Saulle, S. Yahyaei, M. Biasin, M. Garziano, M. Masetti, A. Berzi, D. Trabattoni, S. Lo Caputo, F. Massotta, M. Clerici

Italy

**MOPEA017**
Immune activation is present in HIV-1 exposed seronegative individuals (HESN) and is independent from microbial translocation

M. Garziano, I. Saulle, F. Gnudi, M. Masetti, A. Berzi, F. Massotta, S. Lo Caputo, D. Trabattoni, M. Biasin, M. Clerici

Italy

**PEA018-A200**
**Correlates of immune protection**

www.ias2015.org
Monday 20 July | Poster Exhibition

MOPEA018 Association of the presence of HIV-1 broadly neutralizing antibodies during pregnancy and prevention of mother to child transmission at delivery
T. Mduluza, S. Dzoro, K. Bedi, S. Mpoloka, S. Gaseitsiwe, R. Musonda
Zimbabwe

MOPEA021 Effect of rectal gonorrhea and chlamydia on cytokine expression and HIV viral load in the rectum
O. Davies, J. Tiraboschi, S. Costelloe, J. White, S. O'Shea, J. Fox
United Kingdom

MOPEA023 HIV-1 Nef controls cellular invasion through differential modulation of host proteins
India

PEA28 Adjuvants
MOPEA28 Modulation of binding antibody responses to trimeric gp145 and gp41 HIV-1 envelope proteins by utilizing different adjuvants and delivery platforms as a prime-boost strategy
K. Peachman, G. Gao, O. Jobe, C. Alving, V. Rao, M. Rao
United States

PEA021-A023 Mucosal transmission
MOPEA021 Effect of rectal gonorrhea and chlamydia on cytokine expression and HIV viral load in the rectum
O. Davies, J. Tiraboschi, S. Costelloe, J. White, S. O'Shea, J. Fox
United Kingdom

MOPEA022 CD161-expression on CD4+ T cells is enriched in the female genital tract and identifies a subset of activated cells rather than Th17 commitment as in blood
Canada

PEA023 Novel vectors and strategies
MOPEA029 pVLP: a new DNA vaccine strategy for HIV
A. Calazans, R. Lindsay, G. Morrow, C. Parks
Brazil

MOPEA030 Deletion of immunomodulatory A44L, A46R and C12L viral genes from Modified Vaccinia Ankara (MVA) genome: effect on its immunogenicity
Argentina

MOPEA031 Generating an anti-HIV vaccine using lipid nanoparticle-encapsulated nucleoside-modified mRNA encoding envelope
N. Pardi, M. Hogan, J.A. Hoxie, D. Weissman
United States

MOPEA032 Immunological characterization of an HIV vaccine comprised of Gag and gp41 virus-like particles produced both in plants and by live Vaccinia virus vectors
L. Meador, S. Kessans, J. Kilbourne, K. Kibler, T. Mor, B. Jacobs
United States

PEA024 Founder viruses/transmission bottleneck
MOPEA024 Galectin-3 promotes HIV-1 cell-to-cell transmission via up-regulating GM1 ganglioside in lipid raft of CD4+ T cells
Taiwan, China

PEA025 Acute and early infection
MOPEA025 Early antiretroviral treatment (ART) fails to achieve sustained HIV viral remission but limits viral diversity
P. Zancai, P. Palma, H.K. Tchidjou, G. Liuzzi, C. Alteri, A. Bertoli, C.F. Perro, P. Rossi, S. Bernardi
Italy

PEA026 Strong functional constraint at residues in HIV-1 Gag are predicted by measures of evolutionary rather than population-level genetic conservation
M. John , S. Gaudieri, A. Chopra, S. Leary, J. Jornitsma, S. Mallai, B. Baraki, M. Brockman, Z. Brumme
Australia

PEA027 Effect of losartan on lymphoid tissue fibrosis and inflammation in virologically suppressed HIV patients after 48 weeks
Spain

MOPEA026 T cell-based vaccines
MOPEA026 Strong functional constraint at residues in HIV-1 Gag are predicted by measures of evolutionary rather than population-level genetic conservation
M. John, S. Gaudieri, A. Chopra, S. Leary, J. Jornitsma, S. Mallai, B. Baraki, M. Brockman, Z. Brumme
Australia

MOPEA035 Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeys
Canada
Monday 20 July | Poster Exhibition

**MOPEA036** Safety and immunogenicity of ChAd.HIVconsv and MVA.HIVconsv therapeutic vaccines in a cohort of early treated HIV-1 infected individuals
Spain

**MOPEA037** Development of a latency reversing activator vaccine (ACT-VEC) platform for HIV-1 cure therapy
J.F.S. Mann, T. Biru, P.T. Willie, K. Klein, E.J. Arts
Canada

**MOPEA038** VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IMPROTECT1 multicenter European study
France

**MOPEA039** Broadly specific, cytolytic T cell responses and lower inflammatory responses correlate with durable viral remission following therapeutic DNA vaccination in SIV-infected macaques
D. Fuller, A. Narendran, P. Rajakumar, J. Che, E. Yager, C. Stagmar, M. Murphy-Corb
United States

**PEA040** HIV-1 super-infection/inter/inter subtype co-infection
MOPEA040 Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda
Canada

**PEA041-A042** HCV

**MOPEA041** Stability of the NS3 Q80K polymorphism over time within HCV genotype 1a infected patients
J. Joy, W. Dong, C. Chui, C. Brumme, A. Poorn, P.R. Harrigan
Canada

**MOPEA042** Discovery of a novel class of naturally occurring indirect-acting antiviral agents against both HIV-1 and hepatitis C virus infection
Canada

**PEA043-A044** Novel assays of immune responses

**MOPEA043** Changes in concentrations of circulating calprotectin and S100A9 in successfully treated HIV-1 patients over time
Canada

**MOPEA044** External quality assurance improves both domestic and international laboratory performance for peripheral blood mononuclear cell cryopreservation
R. Coombs, J. Bainbridge, M. Cooper, R. Louzao, W. Routree, J. Darden, A. Weinberg, C. Rinaldo, R. Bosch, J. Ward Jr, T. Denny
United States

**PEA045-A046** Novel assays for assessment of ARV resistance/tropism

**MOPEA045** Applying TRIP technology to visualise latent HIV-1 integrations on chromosome landscapes
H.-C. Chen, A. Jordan, G. Filion
Spain

**MOPEA046** Determination of integrase inhibitor resistance using a novel HIV phenotype assay
M. Robbins, P. Cheung, W. Zhang, M. Sidhu, K. Logue, G. Taylor, Z. Brumme, M. Brockman, P.R. Harrigan
Canada

**PEA047** Animal models of transmission, disease resistance and progression
MOPEA047 SIVagm from vervet African green monkeys can utilize non-CCR5 entry pathways in vitro and ex vivo
N. Riddick, S. Whitted, R.M. Goeken, J.M. Brenchley, V.M. Hirsch
United States

**PEA048** Novel animal/virus models for vaccine, cure research, and inhibitor development
MOPEA048 Probing and characterizing resistance to integrase inhibitors using simian immunodeficiency virus 239
S.A. Hassounah, Y. Liu, T. Mesple&#76;de, M. Oliveira, P.K. Quashie, D. Moisi, P.A. Sandstrom, B. Brenner, M.A. Wainberg
Canada

**Track B > Clinical Science**

**PEB148-B151** Impact of co-factors / viral clade / tropism / genetic factors / age on disease progression

**MOPEB148** Antiretroviral resistance following first-line antiretroviral therapy failure across diverse middle-income settings in the SECOND-LINE study

**MOPEB149** Factors associated with incomplete immunologic recovery in HIV-infected patients with clinical and virologic success after 10 years of antiretroviral therapy: a prospective cohort study

**MOPEB150** Rate of CD4 decline and factors associated with rapid CD4 decline in asymptomatic HIV-infected patients
N. Chaiyasit, S. Sungkanuparph
Thailand

**MOPEB151** Children and adolescents infected with HIV-1 subtype F or BF recombinants failing ARV therapy shows a more extensive resistance profile to protease inhibitors
P.M. Guimarães, J. Cavalcanti, A. Campeas, J.L. Ferreira, F. Cabral, R. Palasio, F. Almeida, L. Brigido
Brazil

**PEB152** Long-term non-progressors and elite controllers

www.ias2015.org
Monday 20 July | Poster Exhibition

MOPEB152 Hospitalizations among HIV controllers versus persons with medically-controlled HIV
T. Crowell, A. Ganasan, S. Berry, R. Deiss, B. Agan, J. Okulicz, Infectious Disease Clinical Research Program (IDCRP) HIV Working Group United States

MOPEB153 Disease burden: morbidity / mortality / life expectancy
Advancing in age: what effect on mortality and loss to follow-up in the course of ART? The IeDEA West Africa cohort collaboration
N. de Bekeoere, E. Balestre, P. Coffie, S. Eholle, E. Messou, V. Kwaghe, O. Benson, A. Sadawago, Y. Abo, F. Dabis France

MOPEB154 Cause of death comparison in a US HIV-infected patient cohort and the National Death Index

MOPEB155 Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the ICONA cohort
A. Mannone, R. Cauda, V. Vullo, C. Viscoli, P. Caramello, F. Baldello, P. Bonfanti, G. Angarano, A. Antinori, M. Puoti, A. D’Arrminio Monforte, E. Girardi, ICONA Foundation Study Group Italy

MOPEB156 Reduction in mortality rates among HIV-positive people who inject drugs in Vancouver, Canada, during a treatment-as-prevention-based HAART scale up initiative: a gender-based analysis
K. Hayashi, T. Kerr, H. Dong, S. Dobrer, S. Guillermi, R. Hogg, J. Montaner, E. Wood, M.-J. Milloy Canada

MOPEB157 Comorbidities of patients with newly diagnosed human immunodeficiency virus (HIV) in the USA: a longitudinal analysis of incident HIV patients
N. Meyer, X. Song United States

MOPEB158 Opportunistic infections (excluding TB)
Clinical presentation and management of parvovirus B19 associated red cell aplasia: experience at the tertiary care institute in Durban, South Africa
M.-A. John, T. Manzini, C. Du Plessis, B. Gosnell, Y. Moosa South Africa

MOPEB159 Tuberculosis and other mycobacteria
CYP2B6 genotype based efavirenz dose recommendations during rifampicin based anti tuberculosis co-treatment for a sub-Saharan Africa population

MOPEB160 Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review
R.K. Gupta, S.B. Lucas, S.D. Lawn United Kingdom

MOPEB161 Other bacterial infections and parasitic infections (including malaria)
Augment of CD4+Tcells count and decrease of cellular activation are observed in HIV-co-infected patients with first episode of visceral leishmaniasis but not in those with previous VL relapses
J. Santos-Oliveira, M.L. Silva-Freitas, G. Cota, P. Dias-Lins, C. Giacoia-Gripp, A. Rabello, A. Da-Cruz Brazil

MOPEB162 Population-based, active TB case finding during large-scale, mobile HIV testing campaigns in rural Uganda
F. Ssemombo, F. Mwangwa, J. Kiironde, D. Kwarislima, T. Clark, E. Charlebois, M. Kamya, D. Havlir, G. Chamb Uganda

MOPEB163 Is prophylaxis against tuberculosis required for HIV-infected individuals in low incidence settings?
K. Manavi, J. Hosdon United Kingdom

MOPEB164 The role of new molecular TB tests in South Africa’s Xpert MTB/RIF algorithm: evaluation of Abbott RealTime MTB assay
A. David, M. Nduna, A. Black, W. Stevens, L.E. Scott South Africa

MOPEB165 Optimal timing of initiation of antiretroviral therapy in HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis of randomised controlled trials
O. Uthman, C. Okwundu, K. Gbenga, J. Volmink, D. Dowdy, A. Zumla, J. Nachega United States

MOPEB166 Prognostic indicators for severely ill HIV-infected patients with suspected tuberculosis
R. Griessel, A. Stewart, H. van der Plas, W. Sithkhondez, M. Nicol, M. Mendelson, G. Maartens South Africa

MOPEB167 Performance of latent TB infection diagnostics in HIV-infected pregnant women in western Kenya
S. LaCourse, L. Cnannner, D. Matemo, J. Kinuthia, D. Horne, G. John-Stewart United States

MOPEB168-B170 Other bacterial infections and parasitic infections (including malaria)

MOPEB168 Augment of CD4+Tcells count and decrease of cellular activation are observed in HIV-co-infected patients with first episode of visceral leishmaniasis but not in those with previous VL relapses
J. Santos-Oliveira, M.L. Silva-Freitas, G. Cota, P. Dias-Lins, C. Giacoia-Gripp, A. Rabello, A. Da-Cruz Brazil

MOPEB169 Causes of hospitalization among people living with HIV/AIDS: a global review

MOPEB170 Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan patients on antiretroviral therapy: a randomized placebo controlled study

PUB171 Syphilis
Repeat syphilis among HIV-infected patients: a nationwide population-based cohort study in Taiwan
Y.-C. Chen, N.-Y. Lee, C.-W. Li, H.-Y. Liu, N.-Y. Ko, W.-C. Ko Taiwan, China

www.ias2015.org 4 / 16
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEB177</td>
<td>Cryptococcal immune reconstitution inflammatory syndrome in HIV-infected Ugandans is associated with memory T cell phenotype and increased GXM capsule-specific cytokine responses</td>
<td>D. Meyy, S. Okurut, P. Brent, G. Ziziwa, S. Cosse, F. Bohjanen, D. Boulware, Y. Manabe, E. Janoff</td>
<td>Uganda</td>
</tr>
<tr>
<td>PEB180</td>
<td>What men don’t know can hurt them. Prospective survey on syphilis knowledge and behaviors in the ANRS CO3 Aquitaine cohort of HIV-infected men, 2014</td>
<td>A. Valdes, C. Cazanaeve, F. Dabis, D. Neau, D. Lacoste, V. Gaboniere, S. Farbos, M. Dworkin, Groupe D’Epidémiologie Clinique du Sida en Aquitaine (Gecsa)</td>
<td>France</td>
</tr>
<tr>
<td>PEB183</td>
<td>Cryptococcal immune reconstitution inflammatory syndrome in HIV-infected Ugandans is associated with memory T cell phenotype and increased GXM capsule-specific cytokine responses</td>
<td>D. Meyy, S. Okurut, P. Brent, G. Ziziwa, S. Cosse, F. Bohjanen, D. Boulware, Y. Manabe, E. Janoff</td>
<td>Uganda</td>
</tr>
<tr>
<td>PEB186</td>
<td>Virological response among HIV-infected pregnant and lactating women initiated on Option B+ attending the PMTCT program at Mulago National Hospital, Kampala, Uganda</td>
<td>J. Pintye, A. Langat, B. Singa, J. Kinuthia, B. Odeny, A. Katana, L. Nganga, G. John-Stewart, C. McGrath</td>
<td>United States</td>
</tr>
<tr>
<td>PEB187-B189</td>
<td>Socio-demographic and clinical predictors of preterm births, low infant birth weight, and pregnancy complications among women living with HIV (WLWH) in Ontario, Canada</td>
<td>R. Keshmiri, I. S. Greene, M. Yudin, K. Murphy, F. Smaill, S. Walmisley, A. Carvalhal, M. Loutfy</td>
<td>Canada</td>
</tr>
</tbody>
</table>
MOPEB188 From option A to B+: exploring challenges of navigating evolving PMTCT strategies among postpartum women living with HIV in rural Uganda
United States

MOPEB189 Integration of TB screening in Kenyan PMTCT programs
United States

MOPEB190 Reproductive choices of women with HIV-1 infection: the ELLA study
United States

PEB191-194 Other sex- or gender-specific issues

MOPEB191 Safety, tolerability and efficacy of dual therapy in women in the GARDEL study
M.I. Figueras, M.J. Roland, P. Patterson, J. Andrade Villanueva, J. Ballestros, J. Gathe, J.R. Lama, J.R. Arríbas, P. Cahn, the GARDEL Study Group
Argentina

MOPEB192 Intimate partner violence among HIV-infected pregnant women initiating antiretroviral therapy in South Africa
United States

MOPEB193 Antiretroviral drug use in a cohort of HIV-uninfected women in the United States
United States

MOPEB194 Coercive sex as a mode of HIV acquisition among a cohort of women with HIV in Canada: an under-recognized public health concern
Canada

PEB195-197 Pharmacokinetics / pharmacodynamics / pharmacogenomics in children and adolescents

MOPEB195 A pharmacokinetics-based adherence measure for antiretroviral therapy in HIV-infected Kenyan children
United States

MOPEB196 Raltegravir (RAL) pharmacokinetics (PK) and safety in HIV-1 exposed neonates at high-risk of infection (IMPACT P1110)
United States

MOPEB197 Prevalence and correlates of CYP2B6-G516T polymorphisms in a cohort of HIV-infected women and children in Canada
F. Kakkar, S. Valois, D.G. Ramsey, A.M. Rezgui, V. Gagne, V. Lamarre, N. Lapointe, H. Soudéyns, P. Ovetchkine, M. Krajnovic
Canada

PEB198 Therapeutic drug monitoring in children and adolescents

MOPEB198 Very high levels of drug resistance in HIV-infected children failing first line ART in Bobo-Dioulasso, Burkina-Faso
France

PEB199-B200 Drug formulations in children and adolescents

MOPEB199 Two open label, randomized, cross-over, single-dose, bioavailability evaluations of abacavir sulfate/lamivudine dispersible tablets 60/30mg resp. 120 mg/60mg compared with that of EPZICOM® 600/300 mg tablets under fasting conditions
A. Deshmukh, S. Chakraborty, R. Chetan, A. Jaiswal, C. Issa, R. Dhole, A. Nagaraj, P. Deshpande, A. Kanda, E. Patras
India

MOPEB200 Relative bioavailability of a dolutegravir (DTG) dispersible tablet and the effect of low and high mineral content water on the tablet in healthy adult volunteers
S. Weller, F. Jerva, A. Buchanano, M. Holton, I. Conn, M. Choukour, H. Song
United States

PEB201-204 Adherence in children and adolescents

MOPEB201 Virological suppression among adolescents and young adults living with HIV in Canada
Canada

MOPEB202 Treatment interruptions common among adolescents and young adults living with HIV in Canada
Canada

MOPEB203 Antiretroviral therapy adherence in perinatally-infected adolescents in Cape Town, South Africa
South Africa

MOPEB204 Managing children and adolescents with HIV treatment failure: results from a pilot project in Khayelitsha
J. Bernheimer, G. Patten, G. Van Cutsem, A. Shroufi, T. Makeleni, N. Mantangana, N. Dumile, V. Cox
South Africa

PEB205-B209 HIV-exposed uninfected children (including effects of ART exposure during pregnancy)
Monday 20 July | Poster Exhibition

MOPEB205 The effects of maternal HIV infection on infectious morbidity of HIV exposed uninfected (HEU) infants in South Africa
A. Slogrove, M. Cotton, T. Kollman, D. Speert, M. Esser, J. Singer, J. Bettinger
South Africa

MOPEB206 Perturbations in gut microbiome in infants born to HIV-infected mothers are related to maternal microbiome and human milk oligosaccharides
United States

MOPEB207 Health outcomes among HIV-exposed uninfected infants in Quebec, Canada
S. Wizman, S. Valois, H. Soudeyns, N. Lapointe, V. Lamare, F. Kakkar
Canada

MOPEB208 Leukocyte telomere length (LTL) dynamics in a cohort of HIV-exposed uninfected (HEU) infants exposed to combination antiretroviral therapy (cART) in utero
A. Ajaykumar, H. Soudeyns, F. Kakkar, J. Brophy, A. Bitun, A. Alimenti, D. Money, A. Albert, H. Côté, CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
Canada

MOPEB209 Effects of smoking on telomere length in cohorts of HIV+ and HIV- pregnant women and HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU) infants
A. Ajaykumar, S. Saberi, B. Sattha, A. Albert, A. Alimenti, E. Mann, J. Van Schalkwyk, D. Money, H. Côté, CIHR Team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
Canada

PEC399 Assessment of population viral load in epidemiology studies

MOPEC398 Genital inflammatory profiles associated with progestin-only injectable contraception and reproductive tract infections among women at high-risk of HIV
United States

MOPEC399 Validating a self-report measure for assessing viral suppression in observational studies: an analysis of linked survey and clinical data from the Canadian HIV women’s sexual and reproductive health cohort study
Canada

PEC400 Modelling the epidemiological impact of large-scale prevention programmes: approaches and results

MOPEC400 Impact of ART rollout on risky sexual behavior among HIV-negatives in rural KwaZulu-Natal, South Africa
N. Haber, F. Tanser, K. Herbst, D. Pillay, T. Bärnighausen, Wellcome Trust Africa Centre for Health and Population Studies
United States

PEC401 STI control to prevent HIV transmission

MOPEC401 Factors influencing prevalence of HIV/AIDS among men who have sex with men (MSM) aged 18-24yrs in Mtswapa Town, Kliifontein, Kenya
Q. Irunu
Kenya

PEC402 Male and female condoms and other physical barriers
Monday 20 July | Poster Exhibition

MOPEC402 Discordance in unprotected sex reporting among African HIV serodiscordant couples
Kenya

PEC403-Male circumcision

MOPEC403 Satisfaction and discomfort in PrePex? device circumcision in Mozambique: programmatic implications
B. Cummings, H. Muquingue, E. Necochea, M. Mahomed, T. Ferreira, D. Bossemeyer, L. Nhambi, K. Curran
Mozambique

MOPEC404 Using continuous quality improvement approaches and service data to improve management of adverse effects and follow-up of circumcised volunteers: the TASO experience
C. Aoaba, L. SsaIi, S. Okoboi
Uganda

MOPEC405 Safety, feasibility, and acceptability of the PrePex device for adult male circumcision in Malawi
United States

MOPEC406 Effectiveness of a quality improvement strategy on the quality of voluntary medical circumcision services: the Ugandan experience
S. Muhumuza, I. Sebuliba, I. Lutalo, F. Mulekya, R. Baryamutuma, E. Akello, R. King, W. Bazeyo
Uganda

MOPEC407 Satisfaction with receiving voluntary medical male circumcision services in Nyanza, Kenya: a cross-sectional survey
B. Abunah, J. Ombaka, B. Guyah, R. Onkoba
Kenya

MOPEC408 Scaling up of voluntary medical male circumcision (VMMC) services for HIV prevention in South Western region of Uganda
M. Mera, E. Natumanya Kajungu, B. Nanteza, J. Secien-Palacin, E. Bitarakwate
Uganda

MOPEC409 Projected costs and impacts of increasing coverage of 20- to 29-year-olds as voluntary medical male circumcision is scaled up in Zimbabwe
K. Kripke, K. Hatzold, D. Taljaard, K. Curran, D. Castor, E. Njeuhmeli
Zimbabwe

MOPEC410 Male circumcision and foreskin cutting practices may explain regional variations in HIV prevalence in Papua New Guinea
D. MacLaren, W. McBride, J.M. Kaldor, A. Valley
Australia

MOPEC411 Dorsal longitudinal slit of the penile foreskin may protect men against HIV acquisition in Papua New Guinea
Australia

MOPEC412 Impact and cost of including adolescents ages 10-19 in programs to scale up voluntary medical male circumcision in South Africa
United States

MOPEC413 A sport-based intervention to increase uptake of voluntary medical male circumcision among adolescent male students in Bulawayo, Zimbabwe: process evaluation
South Africa

MOPEC414 Association of demographics and sexual risk behaviour with adverse events among men accessing medical male circumcision in Ekurhuleni North, South Africa
C.M. Chetty-Makkian, V. Molapais, M. Kgampe, O. Lettipe, S. Ginindza, S. Charalambous, M. Maralaanse
South Africa

MOPEC415 Improving quality of voluntary medical male circumcision services thorough mentorship and coaching: an experience of East Central Uganda
Uganda

PEC416-C419 Treatment as prevention

MOPEC416 Assessing TasP implementation one year after the publication of Brazilian national guidelines
M.A. Freitas, A.R. Pascon, F. Mesquita, J. Barbosa
Brazil

MOPEC417 Identification of factors associated with viral suppression and treatment failure when antiretroviral therapy is used for HIV prevention: results from the HIV prevention trials network (HPTN) 052 trial
United States

MOPEC418 Reconciling the individual and community benefits of treatment as prevention through optimizing an HIV testing program
A. Nadaf, A. Adams, S. Kok, A. Rutherford, R. Gustafson, R. Barrios, K. Vasarhelyi
Canada

MOPEC419 Can targeting treatment as prevention to female sex workers in a concentrated HIV epidemic setting lead to local HIV elimination: a modelling study
A. Low, N. Nagot, I. Konate, N. Meda, M. Segondy, P. Van de Perre, P. Mayaud, P. Vickerman, Yerelon Study Group
United Kingdom

PEC421 Vaccines
MOPEC421 Willingness to participate in future HIV vaccine trials among adolescents and young adults (AYA) from the AYAZAZI study in Soweto, South Africa

MOPEC422 Strategies for identifying key populations

MOPEC423 'Meeting a sex partner downtown' as a risk factor for HIV and syphilis infection among MSM and trans women in Lima, Peru: a marker for larger sexual networks?
L.R. Carrera, K.A. Konda, S.R. Leon, G. Calvo, B. Brown, J.D. Klausner, C.F. Caceres Peru

MOPEC424 Transpinay: understanding the Philippine transgender women towards developing transgender-specific HIV prevention programs and related health services
R.P.N. Cortes Philippines

MOPEC425 Playing it safe: a game-based intervention to prevent HIV among young men who have sex with men in Mexico City
R. Buzdugan, Z. Andrade-Romo, L. Chavira-Razo, G. García-Plata, R. Grimball, E. Bertozzi, S. Bautista-Arredondo Mexico

MOPEC426 Variations in recruitment yield, costs, and speed and participant diversity across internet or social media platforms in a global study of HIV/AIDS and HIV testing knowledge
R. Merchant, W. Shao, W. Guan, M. Clark, T. Liu, C. Santellaces, D. Cortes United States

MOPEC427 “You care about us”: exploring use of mobile phones to improve retention in care and facility delivery in Tabora, Tanzania

MOPEC428 How effective are innovative strategies that use communication technology in scaling up HIV testing and engaging MSM in HIV awareness? A case study from Thailand

MOPEC429 M-Health, e-Health innovations and social media innovations to optimize HIV/STI test and treat strategies: what is the evidence?
R. Vlij, M. Diaconescu, J. Daher, N. Pant Pai Canada

MOPEC430 Structures, users, benefits, and barriers of social media for communication about HIV prevention and care: a systematic review
T. Taggart, M.E. Grewe, D.F. Conserve, C. Gilwa, M.R. Isler United States

MOPEC431 Active and interactive advertising: social media as a recruitment tool for an HIV vaccine trial in Philadelphia, Pennsylvania
L. Buckingham, J. Becher, C. Voytek, D. Fiore, D. Dunbar, A. Davis-Vogel, I. Frank, D.S. Metzger United States

MOPEC432 Utilization of biometric and mobile technology in a community-based combination HIV prevention study

MOPEC433 Effectiveness of text messaging to increase adolescent engagement in prevention
M. Lightfoot, A. Bennett, J. Jackson-Morgan, L. Pollack United States

MOPEC434 Cost of home HIV testing and education for male partners of pregnant women in Kenya
M. Sharma, C. Farquhar, J. Kinuthia, A. Osoti, V. Asila, S. Parikh, A. Gone, D. Krakowiak, R. Barnabas United States

MOPEC435 Partner notification services to identify and refer people living with HIV for care and treatment in Cameroon 2007-14

MOPEC436 Validation of the Denver HIV risk score for targeting HIV screening in Vancouver, British Columbia
T. Falasinnu, P. Gustafson, S. Wong, D. Haag, J. Wong, G. Ogilvie, M. Gilbert, J. Shoveller Canada

MOPEC437 Provider’s role in comprehensive sexual health screening and education for YBMSM aged 15–19
R. Arrington-Sanders, A. Morgan, J. Oldman, D. Fortenberry United States

MOPEC438 Efficacy of structural interventions and social protection

MOPEC439 The role of male circumcision and antiretroviral drugs in the evolution of the HIV and HSV-2 epidemics in Orange Farm (South Africa) between 2002 and 2012 (ANRS-12126 -12285)

MOPEC440 Mixed HIV testimonies, enabling access to information, debate and above all prevention in the younger generation. 30 minutes-English subtitle
E. Carbonnel France
Monday 20 July | Poster Exhibition

**PEC443-C446** Reducing pre-partum and intra-partum transmission to infants

MOPEC443 Prevalence and correlates of *Mycoplasma genitalium* among HIV-infected pregnant African women and implications for MTCT

A. Roxby, K. Yuhas, C. Farquhar, J. Kiarie, S. Graham, G. John-Stewart, P. Totten
United States

MOPEC444 Higher than expected HIV prevalence and risk factors for newly diagnosed versus known HIV infection in an antenatal clinic in Western Kenya

A. Osoti, J. Kinuthia, D. Krakowiak, B. Betz, J. Mark, S. Parikh, A. Gonen, V. Asila, J. Kiarie, C. Farquhar, HOPE Study Group
United States

MOPEC445 Successes and failures of vertical HIV transmission prevention efforts in Canada: evidence from the Canadian Perinatal HIV Surveillance Program (CPHSP)

Canada

MOPEC446 HIV positivity among HIV exposed infants and turnaround time (TAT) for EID results in Iringa and Njombe regions: analysis of results from DNA-PCR laboratory and follow-up on ART initiation

R. Kisanga, P. Ndayanga, J. Ng’weshemi, P. Swai, O. Were
Tanzania, United Republic of

**PEC447** Reducing post-partum transmission in infants

MOPEC447 Systematic review of perinatal HIV transmission from breastfeeding for up to twelve months when the mother has viral suppression with combination antiretroviral therapy

Canada

MOPEC449-C455 Strategies to increase HIV testing in pregnant women and their partners

**PEC449** Invitation cards during pregnancy enhance male partner involvement in prevention of mother to child transmission (PMTCT) of human immunodeficiency virus (HIV) in Blantyre, Malawi: a randomized controlled open label trial

Malawi

**PEC450** Improving PMTCT service uptake through integration into maternal, neonatal and child health week in a high prevalence setting

O. Akinleye, G. Dura, D. Chamila, A. De Wagt
UNICEF

**PEC451** A rapid structured assessment of health facilities for PMTCT scale up in four states in Nigeria with high prevalence

A.C. Alibola, B. Oyeledun, A. Inedu, C. Imaraigbe, B. Uguje, P. Jwanle, E. Madina
Nigeria

**PEC452** Partner antenatal attendance associated with partner HIV testing among pregnant women in Kisumu, Kenya

D. Krakowiak, J. Kinuthia, A. Osoti, V. Asila, M.A. Gone, B. Betz, S. Parikh, C. Farquhar
United States

**PEC453** Where are pregnant women who were not tested for HIV? The use of IQSMS in identifying pregnant women for HIV testing, Tanga experience, Tanzania

T.S. Tulli, D. Mwikali, A. Mourad, S. Jongo, G. Binde, A. Madhehebi
Tanzania, United Republic of

**PEC454** Systematic HIV-testing in delivery rooms is feasible: a pilot program through 8624 consecutive deliveries in Burundi, East Africa

H. Leroy, S. Manyundo-Risase, B. Ninyibutse, J. Bizirugusenyuka, N. Cartier, C. Arvieux
France

**PEC455** Infant HIV outcomes and timing of presentation to prenatal care: contribution of HIV seroconversion during pregnancy

M. Melo, J. Raney, K. Nielsen-Saines, T. Rocha, B. Santos, I. Varella
United States

**PEC457-C469** Increasing coverage and quality of PMTCT programmes

MOPEC457 Characteristics and outcomes of women initiating ART during pregnancy versus breastfeeding in Option B+ in Malawi

M. Landes, S. Soodi, A. Matengeni, C. Meaney, M. van Lettow, A.K. Chan, J. van Oosterhout
Canada

MOPEC458 Dramatic improvements in uptake of prevention of mother to child HIV transmission services in Zimbabwe, 2012-2014

S.I. McCoy, R. Buzdugan, M. Kang Dufour, R. Musarandaga, A. Mushavi, A. Mahomva, B. Engelsmann, N.S. Padian, F.M. Cowan
United States

MOPEC459 Acceptability of prevention of mother to child transmission of HIV Option B+ among HIV-infected pregnant and breastfeeding women in Chiradzulu District, Malawi

T. Mwapa, A. Muula
Malawi

**PEC460** Same day integration of HIV diagnosis and treatment with antenatal care affects retention in Option B+ prevention of mother to child transmission services in Zomba District, Malawi

A.K. Chan, E. Kanike, R. Bedell, I. Mayuni, R. Manyera, W. Miotha, A.D. Harries, M. van Lettow
Malawi

**PEC461** Predictors and outcomes of perinatal HIV transmission at regional referral hospitals implementing Option B plus in Uganda

C. Katurebe, I. Lukabwe, M. Kwikiriza, E. Namagala, N. Tumwesigye
Uganda

www.ias2015.org
| MOPEC462 | Male partner involvement improves uptake of prevention of mother to child HIV transmission services in Kenya | B.M.O. Odeny, C. McGrath, J. Kinuthia, B. Singa, A. Langat, J. Pintye, A. Katana, L. Nganga, G. John-Stewart | United States |
| MOPEC463 | Male partner participation in antenatal clinic services is associated with improved mortality and HIV-free survival among infants of HIV-positive women in Nairobi, Kenya: a prospective cohort study | A. Aluizio, R. Bosire, B. Betz, C. Farquhar | United States |
| MOPEC465 | National estimates of mother to child transmission of HIV-1 at 6 weeks and 9 months in India | C. McGrath, B. Singa, A. Langat, J. Kinuthia, K. Ronen, D. Omolo, E.B. Odongo, R. Wafuha, P. Muange, A. Katana, L. Nganga, G. John-Stewart | United States |
| MOPEC466 | The action birth card: evaluation of an innovative goal-setting tool to increase demand and uptake of underutilized services along the PMTCT cascade | K. Webb, V. Chituyo, D. Patel, A. Chari, A. Dhlania, M.-A. Nicholas, E. Kennedy, B. Engelsmann | Zimbabwe |
| MOPEC467 | Awareness, utilization and access to HIV and maternal health care services for pregnant women in two high HIV prevalence districts of India: a baseline evaluation | J. Behar, A. Sarkar, G. Mburu, P. Sharma, S.K. Mishra, S. Mehra | India |
| MOPEC469 | Why did I stop? Barriers and facilitators to acceptance of and retention in the Option B+ program in Lilongwe, Malawi | M. Kim, A. Zhou, A. Mazenga, S. Ahmed, C. Markham, G. Zomba, P.N. Kazembe, E.J. Abrams | United States |
| PEC470 | PMTCT services for marginalized groups | | |
| PEC471-C472 | Integration of family planning and HIV services | | |
| PEC471 | Unplanned pregnancies and unmet family planning needs among HIV-1-discordant couples in Nairobi, Kenya | K. Mancuch, C. Farquhar, R. Bosire, J. Klare, B. Guthrie | United States |
| PEC473-C475 | Promoting health and reducing maternal mortality in HIV positive women | | |
| PEC473 | Loneliness and perceived social support in mothers living with HIV in Ontario | S. Khan, A. Ion, R. Keshmiri, S. Greene, S. Waismley, L. Kennedy, M. Loutfy | Canada |
| PEC474 | Breastfeeding did not have negative impact on body mass index of HIV-infected mothers in 4 African countries | E.N. Somé, I.M. Engebretsen, N. Meda, N. Nagot, R. Vallo, M. Péries, C. Kankansa, J. Tumwine, J. Hofmeyr, P. Van De Perre, T. Tylleskar, ANRS 12174 Trial Group | Burkina Faso |
| PEC475 | Postpartum transfer of care among HIV-infected women who initiated antiretroviral therapy during pregnancy: a cohort study | T. Phillips, M. McNairy, A. Zerbe, L. Myer, E.J. Abrams | United States |
| PEC476-C477 | Prevention addressing gender inequalities | | |
| PEC479-C480 | Reproductive choices and interventions for women (including discordant couples) | | |
| PEC479 | High levels of unmet need for family planning among HIV-infected women participating in an open HIV community cohort study in rural Tanzania: implications for HIV prevention and service integration | A. Wringle, K. Church, A. Aveika, J. Todd, D. Michael, B. Zaba, M. Urassa | United Kingdom |
| PEC481 | Population-based intervention studies | | |
| PEC481 | Treatment as prevention (TasP) in rural Swaziland: initiating the change towards universal treatment in the public health sector | B. Kerschberger, A.H. Bakri, S. Mazibuko, I. Zabsonre, S.M. Kabore, R. Teck, I. Ciglenecki | Swaziland |
MOPEC489  Economic-based HIV interventions (i.e., microcapital/cash transfer/contingency management/housing/poverty reduction programmes)

MOPEC482  The impact of a multisectoral agricultural and finance intervention on nutritional and HIV health outcomes in rural Kenya

MOPEC483  Economic incentives to increase demand for voluntary medical male circumcision in Kenya: qualitative interviews with participants in a randomized controlled trial

PEC482-C485  Assessing impact/cost-effectiveness of structural interventions

MOPEC484  Evaluating the impact of health system strengthening on HIV and sexual risk behaviors in Nigeria

MOPEC485  Model the impact of needle and syringe program on HIV incidence: how to gain more

PEC486  Gender sensitization, empowerment and violence reduction

MOPEC486  Understanding the violence cycle and the impact of structural interventions reducing different forms of workplace violence perpetrated against female sex workers: implications for HIV prevention

PEC487  Research designs in epidemiology

MOPEC487  What is the effect of including online-recruited seeds within an in-person bio-behavioural study of men who have sex with men (MSM) employing respondent-driven sampling (RDS)?

PEC488-C492  Research designs in prevention research

MOPEC488  Implementing electronic coupons within respondent-driven sampling (RDS) to improve recruitment of men who have sex with men (MSM) in Vancouver, British Columbia

MOPEC489  Effect of antiretroviral therapy on diarrhoea incidence and stool pathogens among HIV-infected individuals in rural Uganda: a prospective population-based cohort study

PED681-D686  Methodological challenges to scale up and optimization of services
| MOPED681 | Survey of healthcare professionals on the role of pharmacists in an outpatient HIV clinic setting | Investigating the influence of peer mentor mother approach on the psychosocial well-being of HIV-positive pregnant women and new mothers accessing prevention of mother to child transmission of HIV services |
| MOPED682 | Perspectives of HIV-infected adolescents on disclosure of HIV status in Western Kenya | Impact of harm reduction interventions under the community action on harm reduction 'Hridaya' programme on safe injecting and sexual behaviours among people who inject drugs in India |
| MOPED683 | Criminal justice involvement and the continuum of HIV care among people who inject drugs or smoke crack cocaine in Oakland, CA, USA | Clinical outcomes of HIV care delivery models in the US: a systematic review |
| MOPED684 | Lower ART retention by 2010 guideline revision in resource-limited settings, Zambia | Geographical variation in access to HIV care for low-income adults: the case of Virginia |
| MOPED685 | Use of novel geographic information systems (GIS) improves planning, delivery, and tracking of voluntary medical male circumcision (VMMC) scale up in Tanzania | Patient satisfaction with methadone maintenance treatment in Vietnam: a comparison of standalone- and integrative- service delivery models |
| MOPED686 | Analysis of the change in facility-level ART unit costs after implementation of the new WHO treatment guidelines in Malawi | Using unique identifiers with key population HIV prevention programmes to measure coverage, prevalence and incidence: TB/HIV Care Association's sex worker HIV prevention model and data from Durban, South Africa |
| PED6787-D698 | Impact evaluation of different models of service delivery | Long-term ART outcome and operational challenges in rural health centres supported by mobile team: a prospective cohort study in a rural district, Zambia |
| PED6877 | Text message reminder-recall to increase HPV immunization uptake in young HIV-1-infected patients | Scaling up access to second line antiretroviral therapy in rural Zimbabwe: impact of routine viral load, model of care and re-suppression after switch |
| PED6888 | Health system modelling to evaluate operational strategies for the implementation of UNAIDS 90-90-90 targets in Vancouver, Canada | Scale up of point-of-care technologies |
| PED6899 | Healthcare provision for truck drivers in sub-Saharan Africa: a systematic review of interventions, methods of evaluation and impact | Effects of clinical flow and patient initiation mentorship on point-of-care CD4 testing |
| PED6900 | The cost-effectiveness of the mothers2mothers Mentor Mother Model as a psychosocial well-being intervention | Effect of PIMA point of care instruments for CD4 counting on time to ART initiation in rural Botswana |
| PED7000-D701 | Scale up of point-of-care technologies | Scale up of viral load monitoring |
Monday 20 July | Poster Exhibition

MOPED702 Is CD4 monitoring needed where there is routine viral load? A cohort analysis from Kibera, Kenya
W. Kizito, B.B. Ngoy, H. Ritter, W. Etienne, K. Kranzer, H. Bygrave
South Africa

MOPED703 Introduction of viral load in routine settings in Kenya: implications for programs
Kenya

MOPED704 Adaptive viral load monitoring for second-line ART in Côte d'Ivoire: cost-effectiveness and budget impact analysis
Côte d'Ivoire

MOPED705 Introduction of a routine viral load algorithm in rural Zimbabwe: programmatic strategies for implementation and impact on second line needs
Y. Htung Naing, H. Bygrave, S. Simons, D. Munyaradzi, C. Metcalf, T. Roberts
Switzerland

PED706 National and international financing initiatives

MOPED706 HIV prevention research & development funding trends 2000–2014: investment priorities to fund innovation in an evolving global health and development landscape
United States

PED707 Transitional financing

MOPED707 Planning for the transitioning of PEPFAR investments to Government in Nigeria: Kwara State experience
E. Atuma, A. Ayinla, S. Akande, S. Faramoju, J. Ezekiel, M. Salami
Nigeria

PED708 Leveraging HIV funding to strengthen health systems beyond HIV programmes

MOPED708 Leveraging HIV funding to strengthen health systems beyond HIV programs: a case of infrastructural improvements in East Central Uganda
E. Kazibwe, S. Mashate, M. Kagugube, A. Mugume
Uganda

PED709-D717 Monitoring and evaluation of testing

MOPED709 Two-year performance of an early infant diagnosis program in rural north-central Nigeria
F. Yunusa, B. Harry-Erin, H. Swomen, C. Chime, H. Isah, F. Murtala-Ibrahim, P. Dakum, N.A. Sam-Agudu
Nigeria

MOPED710 The cost of providing rapid HIV testing for screening men who have sex with men in new community sites compares favorably with established clinics in Sydney, Australia
Australia

MOPED711 IQA/UK NEQAS EQA participation and accuracy of patient monitoring in clinical trial networks
J. Bainbridge, W. Rountree, R. Louzao, J. Wong, L. Whitby, T. Denny, D. Barnett
United States

MOPED712 'I did not see a need to get tested before. Everything was going well with my health': a qualitative study of HIV testing in KwaZulu-Natal, South Africa
United Kingdom

MOPED713 Factors associated with low CD4+ count at diagnosis among patients enrolled in a prospective cohort study in KwaZulu-Natal, South Africa
United Kingdom

MOPED714 Increased counseling and testing visits are associated with remaining HIV uninfected
W. Wimonsate, S. Pattanasin, A. Sriporn, P. Luechali, K. Satumay, N. Tippanonth, N. Promda, T. Holtz, A. Chitwarakorn, E. Dunne
Thailand

MOPED715 Shaping care: a case study from Sierra Leone
A. Collins
Canada

MOPED716 Trends in testing outside of traditional settings in England
L. Cieply, S. Collins, C. Penman, S. Mandal, S. Lattimore
United Kingdom

MOPED717 Impact of STOP HIV/AIDS program on HIV, hepatitis C and syphilis testing volumes in British Columbia
T.B. Consolacion, A. Yu, N.Z. Janjua, J. Wong, R. Barrios, J.S.G. Montaner, M. Krajden
Canada

MOPED718-D733 Monitoring and evaluation of treatment and care

MOPED718 Medication possession ratio as a tool for assessing the adherence of antiretroviral therapy among HIV-infected Malaysians: a cross-sectional study
P. Raghavan, S.K. Chidambaram, C. Lee Kwok Choong, R. Mohamad Sani
Malaysia

MOPED719 Improving the provision of antiretroviral therapy (ART) using the community balance scorecard methodology in 8 districts of Malawi
D. Kuphanga
Malawi

MOPED720 Alcohol and depression: link with adherence and viral suppression in patients on antiretroviral therapy in rural Lesotho, Southern Africa
B. Cerutti, O. Fatunyiele, M. Masetsibi, J. Bader, M. Motlatsi, T. Klimmik, L. Toti Mokoteli, C. Hatz, N.D. Labhardt
Switzerland

MOPED721 Achieving viral suppression with antiretroviral treatment (cART) in an Eastern-European HIV population predominantly consisting of people who inject drugs (PWID)
P. Soodla, K. Hulc, H. Rajasaar, M. Pauskar, E. Kallas, E.-L. Jõgeda, M. Maimets, I. Lutsar, R. Avi
Estonia
Monday 20 July | Poster Exhibition

| MOPED722 | Using the Child Status Index (CSI) to measure changes in well-being in orphans and vulnerable children |
| MOPED723 | Transmitted HIV drug resistance survey in two provinces in Papua New Guinea |
| MOPED724 | Declining mortality among HIV-positive Aboriginal people at a Vancouver inner-city health centre |
| MOPED725 | Analysis of ART clinical outcomes |
| MOPED726 | Rate of ART initiation and time to ART initiation among HIV-infected participants in the Bangkok MSM cohort study, 2006-2014 |
| MOPED727 | 12-month costs of care of HIV-infected children initiating early antiretroviral therapy before the age of 2 years in Abidjan, Côte d’Ivoire, 2011-2014. The MONOD ANRS 12206 project |
| MOPED728 | Third-line antiretroviral treatment: the Brazilian experience |
| MOPED729 | UK healthcare providers’ views on antiretroviral therapy in primary HIV infection |
| MOPED730 | Integrating HIVDR early warning indicators with quality improvement to minimize HIVDR occurrence, Thailand |
| MOPED731 | Benefits beyond the patient: a regression discontinuity analysis of the impact of adult antiretroviral therapy (ART) on childhood educational attainment in South Africa |
| MOPED732 | Acceptability of internet and cell-phone messages to promote linkage to HIV care |
| MOPED733 | The effectiveness of compulsory addiction treatment: a systematic review |
| PED735- D753 | Monitoring and evaluation of HIV cascade and vulnerability at the client level: a cross-sectional study in Eswatini |
| MOPED735 | Early retention in care at an HIV outpatient clinic in Rio de Janeiro Brazil, 2000-2013 |
| MOPED736 | Engagement in HIV care among young female sex workers in Zimbabwe |
| MOPED737 | Evaluating the HIV cascade of care: model design, evaluation and results after implementation in one center for 2 consecutive years |
| MOPED738 | Loss of HIV-positive patients in rural primary health care facilities in North West province, South Africa: a retrospective register audit |
| MOPED739 | Treatment as prevention in Brazil: speeding up the pace to reach the 90-90-90 targets |
| MOPED740 | National preventing mother to child HIV transmission program 2014, Thailand |
| MOPED741 | Completeness and accuracy of data in Zimbabwe’s national PMTCT program health facility registers: findings from a patient level data quality audit |
| MOPED742 | Are HIV-positive individuals more likely to engage with HIV care if someone else in the household is HIV-positive and in care? |
| MOPED743 | Predictors of viral suppression and rebound among HIV-positive gay, bisexual, and other men who have sex with men in a large multi-site Canadian cohort |

**www.ias2015.org**
Cost-effectiveness analysis alongside the cascade of HIV care: to seek, test, treat or retain? That is the question

B. Nosyk, J.E. Min, E. Krebs, R. Barrios, J. Montaner, STOP HIV/AIDS Study Group
Canada

Linkage to HIV care among Tebelopele voluntary counseling and testing clients, 2008 - 2012

United States

Linkage to care among HIV-infected infants in Botswana

G. Machao, P. Lekone, A. Lesego, E. Fetogang, N. Prata Menezes
United States

A population-based estimate of documented completion of early infant diagnosis in Mashonaland East Province, Zimbabwe

Zimbabwe

Understanding gaps in service delivery through the HIV diagnosis-to-treatment cascade: findings from health facility surveys in six sub-Saharan countries

Malawi

Linkage to TB treatment in Botswana among Tebelopele clients who screened positive for TB, 2008 - 2012

G. Machao, P. Lekone, T. Lere, B. Kgwaadira, P. Loeto, J. Kabomo, E. Fetogang, D. Voetsch, N. Prata Menezes, E. Kim
United States

The care and treatment cascade and 2020 "90-90-90" targets in Latin America and the Caribbean: baseline 2013 estimates

WHO

Improving engagement in care and viral suppression through health systems linkages and intensive case management: preliminary findings from a multi-city implementation project

M. Peng, R. Westergaard, C. Schumann, A. Meier, T. Hess, J. Vergeront
United States

Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'

B. Nosyk, L. Lourenco, J.E. Min, D. Shopin, V. Lima, J. Montaner, STOP HIV/AIDS Study Group
Canada

Monitoring and evaluation of health systems

M. Peng, R. Westergaard, C. Schumann, A. Meier, T. Hess, J. Vergeront
United States

The cost-effectiveness of population-level HAART expansion in British Columbia

B. Nosyk, J.E. Min, V. Lima, R. Hogg, J. Montaner, STOP HIV/AIDS Study Group
Canada

Using the community score card approach to assess the quality of HIV/AIDS service delivery in public health facilities in Uganda

S. Kentutsi
Uganda